17th November, 2010 - Dublin, Ireland

Cellix are pleased to announce their involvement in the NAMDIATREAM grant, co-ordinated by Prof. Yuri Volkov at Trinity College Dublin. 

NAMDIATREAM = NAnotechnological toolkits for Multi-modal disease DIAgnostics and TREAtment Monitoring  

Funding Amount:  €12 million

Project Dates:  1st July 2010 - 30th June 2014.

Main Objectives:

NAMDIATREAM will develop a cutting edge nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cell indicateive of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices.  The project is built on the innovative concepts of super-sensitive and highly specific lab-on-a-bead, lab-on-a-chip and lab-on-a-wire nano-devices utilizing photo-luminescent, plasmonic, magnetic and non-linar optical properties of nano-materials.  This offers groundbreaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturisation and reproducibility. 

22 PARTNERS across EUROPE from ACADEMIA and INDUSTRY are involved in this project.  For more information, please click here.

Project Update:

NAMDIATREAM Project coordinator, Prof. Yuri Volkov and Dr. Prina-Mello (NAMDIATREAM and ETP-Nanomedicine executive board) attended the ETP Nanomedicine General Assembly where Prof. Volkov highlighted the project ot the ETP-N members and EU Directors, project officers and EMA regulatory agency. 

Upcoming Events:

Second Workshop on Optical Imaging, 25th - 26th November 2010, Göttingen, Germany.

Official NAMDIATREAM website, please click here

About Cellix:

Cellix is an Irish based company producing a range of precise microfluidic pumping solutions and disposable biochips for cell-based assays in applied biological research and drug screening.  Cellix's VenaFlux Platform and customised platforms provide continuous blood flow (via Mirus Nanopump) and simulate blood vessels (via capillaries in our range of biochips) in a robust in vitro micro-environment.  Investigation of platelet biology, thrombi formation, the leukocyte adhesion cascade; biofilm formation and colonisation; and evaluation of stents and stent materials are key applications of our technology where customers cite the "reduction in blood sample required; ease of use and physiological relevance" of the assays as being of key importance.  Customers include academics, blood centers and pharmaceutical and biotechnology companies around the world.  The Company is headquartered in Dublin, and maintains an office in New York city.  For further information on Cellix's biochip range, click here.

For more information, please contact Cellix: 

Tel:  +353-1-896-2799

Email:     This e-mail address is being protected from spambots. You need JavaScript enabled to view it